LONDON, Sept. 8 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (GSK) today announced that Chris Viehbacher, Executive Director and President North American Pharmaceuticals, has decided to stand down from the Board on 8th September, and will leave the company with effect from 1st December 2008 to pursue another opportunity.
Andrew Witty, Chief Executive Officer said: “I would like to thank Chris for his significant contribution to GSK, he is one of the most talented and respected executives in this industry and we wish him well in his future endeavors.”
GlaxoSmithKline -- one of the world’s leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2007.
Source: GlaxoSmithKline
